French venture capital fundraising rebounds but highly concentrated: structural change or temporary phenomenon?

Structural Differentiation Behind the Rebound

After a relatively sluggish 2025, French venture capital fundraising experienced a strong rebound in the first half of 2026. According to PitchBook's *Q2 2026 France Market Snapshot*, French VC fundraising reached €2.4 billion (approximately $2.7 billion) in H1 2026, already exceeding the full-year 2025 total of €1.7 billion. However, this figure does not signify a comprehensive recovery in France's tech financing environment—more than 40% of that amount came from a single fund: the $1.2 billion Jeito II fund closed in March by Paris-based biopharma investor Jeito Capital. This phenomenon reveals an ongoing structural shift in France's venture capital ecosystem: the explosive success of biopharma coexists with a crowding-out effect on fundraising for other industries, while state capital plays an increasingly central supporting role.

Public Capital: A Market Driver, Not a Supplement

Apart from Jeito Capital, another notable fundraising in H1 2026 was Kurma Biofund IV's €215 million, whose LPs include Eurazeo, Australian pharmaceutical company CSL, the European Investment Fund (EIF), and France's national investment bank Bpifrance. Notably, Bpifrance is not just a participant in this fund but also the most influential stakeholder across the entire French VC ecosystem. According to PitchBook data, Bpifrance accounts for approximately 30% of seed-stage and early-stage investments in France, and in February 2025 committed €10 billion to artificial intelligence.

Furthermore, the French government's Tibi 2 plan, launched in 2023, has mobilized over 30 French institutional investors, corporates, and family offices, committing approximately €7 billion to eligible tech funds by the end of 2026. This concentrated injection of public and quasi-public capital has kept French VC fundraising volumes appearing to grow on the surface, but the true diversity of the market may not be as robust as the numbers suggest.

Biopharma: France's Global Competitive Advantage

The massive close of Jeito Capital II was no accident. France possesses a deep scientific research base in life sciences, a high-level clinical research network, and an industrial cluster of multinational pharmaceutical companies. Jeito focuses on late-stage biopharma investments, and its successful fundraising indicates strong global capital recognition of France's innovation potential in this field. This success also reflects a key characteristic of the French VC market: when French companies demonstrate global competitiveness in specific tracks (such as biopharma and deep tech), they can attract substantial international capital, including institutional investors from the U.S., the Middle East, and Asia.

However, this highly concentrated model also carries risks.However, this highly concentrated model also implies risks. Once Jeito II's investment returns fall short of expectations, or the global biomedical market enters a cyclical adjustment, foreign capital may quickly withdraw, and domestic public funds will find it difficult to fully fill the gap. The low point in 2025 (€1.7 billion for the full year) partly reflects the aftermath of the global VC winter since 2024, when the market was mainly sustained by Bpifrance and the Tibi program.

Long-term Impact on the French Innovation Ecosystem

From the perspective of the French economy, the current VC fundraising structure is shaping a "dual-track" ecosystem. On one hand, government priority areas such as biomedicine, artificial intelligence, and clean technology receive ample funding, with Bpifrance's large funds (such as the €750 million Large Venture Fund 3 currently being raised) continuously providing ammunition for these sectors. The €1.5 billion late-stage fund being raised by Atlantic Vantage Point also indicates that some market participants are optimistic about France being able to produce more successful late-stage tech companies.

On the other hand, industries with a higher degree of marketization, such as consumer tech, enterprise SaaS, and fintech, may face the dilemma of further narrowing funding sources. This is because these areas have long investment return cycles, high risks, and lack national policy support. If there is a long-term lack of independent, non-policy-oriented venture capital, the diversity of French tech startups may be suppressed, with over-reliance on government will to select tracks. This is not conducive to cultivating diversified enterprises that can withstand the test of the international market.

France's Positioning in the European Competitive Landscape

Compared with Germany and the UK, the French VC market is more reliant on public capital. Germany has a relatively well-developed pension system and family offices as LPs, while the UK relies on institutional investors in the City of London and a large number of international VC branches. France's model shows resilience in bear markets—because state capital does not easily withdraw—but in bull markets, it may hinder market vitality. For example, among the €7 billion commitments mobilized by the Tibi 2 plan, the actual allocation speed has been slow, with some institutions still on the sidelines.

From the perspective of overall European innovation competition, France is building biomedicine and AI as its differentiated advantages. Bpifrance's €10 billion AI commitment and the French government's "AI National Strategy" proposed in 2025 position France to compete with the UK and Germany in AI foundation models and applications. However, if the French VC market cannot break free from the pattern of "a few large funds + government capital" in the long term, the late-stage fundraising capabilities of its tech companies may be weaker than their American counterparts, or even weaker than other European markets that rely on more diversified LPs.

Long-term Trend Judgment (2026–2036)

In the next 3 to 10 years, the following trends may emerge in the French VC market:1. Sustained Leadership in Biomedicine: The success of Jeito II may drive the establishment of more specialized biomedical funds, increasing France's global share in this field. However, attention must be paid to valuation bubbles and the smoothness of subsequent exit channels (such as IPOs and M&A).

2. Exit Risk of State Capital: The Bpifrance and Tibi plans ultimately need to achieve principal returns. If the funds invested with public capital underperform, it could trigger political pressure, forcing the government to adjust investment strategies. But in the short term, state capital will remain a "stabilizer" for the market.

3. Gradual Penetration of International LPs: As France sees more funds like Jeito that can attract international capital, Middle Eastern sovereign wealth funds, US endowments, etc., may increase their allocation to France. This will help diversify risk and promote the internationalization of French startups.

4. Structural Gap in Early-Stage Financing: Seed and Series A rounds are highly dependent on independent VCs, which are facing fundraising difficulties. If Bpifrance continues to dominate the early stage, there may be a problem of "government taste" directing uniformity, harming innovation diversity.

5. Deep Tech and AI Capital Deepening: France's advantages in quantum computing, nuclear energy, space technology, etc., will attract more state-led capital. These fields typically require long cycles and large investments, where state capital has a unique advantage. But the speed of commercialization and market validation will be key challenges.

In summary, the nature of the rebound in French VC fundraising in the first half of 2026 is a "structural boom" driven jointly by a super fund in the biomedical field and national public capital. This phenomenon reveals the strengths of France's innovation ecosystem—global competitiveness in specific areas, strong government capital mobilization capacity—but also exposes its vulnerabilities: high market concentration, heavy dependence on public capital, and lack of diversity. For the French economy, how to transition from this "two-legged" model (state-driven + biomedical highlights) to a more balanced and market-vibrant ecosystem will be key to determining its position as a European innovation hub over the next decade.